newsfilter
← Latest News
GlobeNewswire·

Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Registrational RESET-Myositis® clinical data on track to be reported in mid-2027 to support 2H27 BLA submission for rese-cel Juvenile myositis Phase 1/2 data expected to be submitted with BLA to support potential FDA